Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 23, Pages 2539-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.21.02543
Keywords
-
Categories
Funding
- NRG Oncology Operations grant [U10CA180868]
- NRG Oncology SDMC grant [U10CA180822]
- NCORP [UG1CA189867]
- NRG Specimen Bank grant from the National Cancer Institute (NCI) [U24CA196067]
- EORTC Translational Research Fund [TRF 01/02]
- AstraZeneca EORTC Translational Research Grant [AZ/01/02]
- Dutch Cancer Society [DDHK 2005-3416, EMC 2007-3932]
- Stichting StopHersentumoren.nl
- Dutch Foundation for Scientific Research ZonMw Programme Translational Research (PTO) [95110051, 92003560]
- William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian Hospital
- Michael Weiner Glioblastoma Research Into Treatment Fund
- NCI/NIH [P30CA013696, UG1CA189960]
Ask authors/readers for more resources
This study reports the final long-term survival results of the European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 trials, comparing radiotherapy with and without PCV chemotherapy for anaplastic oligodendroglial tumors. The results show similar long-term survival rates even without tumor recurrence.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available